Virpax Pharmaceuticals (VRPX) AI Stock Analysis

• Market Cap: $13.79K
• Dividend Yield: N/A
• Average Volume (3M): 1.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: N/A
• EPS Growth: 60.26%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -128.83
• Shares Outstanding: 1,242,504
• 10 Day Avg. Volume: 1,128
• 30 Day Avg. Volume: 1,382
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 300.37
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.34
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 31 Underperform
• Price Target: ―

Virpax Pharmaceuticals is facing significant financial challenges with zero revenue and high cash burn, making its financial performance the most critical factor. Technical indicators show a strong bearish trend, compounded by a delisting notice and leadership changes. The recent capital raise offers some hope, but overall, the outlook remains risky and uncertain.

Positive Factors

Strategic Partnerships

Strategic partnerships and licensing agreements can provide a steady revenue stream and facilitate product development, enhancing long-term growth potential.

Innovative Drug Delivery Systems

The focus on innovative drug delivery systems positions Virpax to improve therapeutic outcomes, potentially capturing market share in pain management and neurological disorders.

Experienced Leadership

The addition of experienced leadership can strengthen strategic oversight and governance, aiding in navigating regulatory challenges and enhancing operational effectiveness.

Negative Factors

Financial Instability

Negative equity and financial instability pose significant risks to operational continuity, requiring urgent strategic pivots or capital injections to sustain business operations.

Zero Revenue

The absence of revenue generation highlights the pre-commercial stage of the company, increasing reliance on external financing and posing long-term sustainability challenges.

Leadership Changes

Frequent leadership changes can disrupt strategic direction and operational stability, potentially impacting investor confidence and the company's ability to execute its business plan.

Virpax Pharmaceuticals Business Overview & Revenue Model

Company Description

Virpax Pharmaceuticals (VRPX) is a clinical-stage pharmaceutical company focused on developing novel drug delivery systems to enhance the efficacy and safety of existing therapeutics. The company primarily operates in the pharmaceutical sector, specializing in pain management, neurological disorders, and anti-viral therapies. By leveraging proprietary delivery technologies, Virpax aims to optimize the delivery of active pharmaceutical ingredients, ultimately improving patient outcomes.

How the Company Makes Money

Virpax Pharmaceuticals makes money through the development and commercialization of its proprietary drug delivery systems and pharmaceutical products. The company's revenue model includes licensing agreements with other pharmaceutical companies and partnerships to co-develop and market their drug candidates. Additionally, Virpax seeks to generate income from milestone payments and royalties derived from successful commercialization of their therapies. Key revenue streams include developmental collaborations and strategic alliances with industry partners that enable the advancement of their product pipeline.

Virpax Pharmaceuticals Financial Statement Overview

Summary

Virpax Pharmaceuticals is heavily reliant on external financing to support its operations amidst zero revenue and burgeoning losses. The financial health is precarious, with negative equity and high cash burn presenting significant risks. Immediate strategic pivots or capital injections are essential to stabilize operations and progress towards commercialization.

Income Statement

Virpax Pharmaceuticals has consistently reported zero revenue, indicating the company is pre-revenue or has not yet commercialized its products. The net losses over the years have widened significantly, with a substantial increase in operating expenses reflected in the negative EBIT and EBITDA. This trend suggests ongoing R&D investment or operational challenges without corresponding revenue generation.

Balance Sheet

The company's financial structure is concerning, with negative stockholders' equity indicating insolvency issues, exacerbated by increasing liabilities and a decreasing asset base. The debt-to-equity ratio is not applicable due to zero debt, but the negative equity highlights a risky financial position needing immediate address to ensure operational continuity.

Cash Flow

Operating cash flow is persistently negative, showcasing cash burn typical of a biotech firm in developmental stages. No free cash flow growth and reliance on financing activities for cash inflow highlight sustainability risks. The absence of revenue and high cash outflows foreshadow long-term liquidity challenges if financing cannot be secured.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-12.08B	-15.19M	0.00	0.00	-4.19M
Net Income	-12.07B	-15.19M	-21.46M	-12.15M	-4.49M
Balance Sheet
Total Assets	1.56B	9.63M	19.67M	39.57M	465.41K
Cash, Cash Equivalents and Short-Term Investments	1.51B	9.14M	19.00M	36.84M	54.80K
Total Debt	0.00	0.00	0.00	0.00	1.57M
Total Liabilities	2.47B	7.69M	3.09M	2.09M	4.68M
Stockholders Equity	-913.76M	1.93M	16.58M	37.48M	-4.22M
Cash Flow
Free Cash Flow	-16.71B	-9.85M	-17.85M	-14.54M	-1.38M
Operating Cash Flow	-16.71B	-9.85M	-17.85M	-14.54M	-1.38M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	9.08B	0.00	0.00	51.33M	1.40M

Virpax Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRPX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.08, and below the 200-day MA of 3.02, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 29.67 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VRPX.

Virpax Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRI	45 Neutral	4.83M	-0.07	0.00%	―	0.00%	98.45%
SCPX	38 Underperform	12.23K	0.00	-520.79%	―	-69.81%	88.78%
VRPX	31 Underperform	$13.79K	―	-2364.82%	―	―	60.26%
SLRX	30 Underperform	2.83M	-0.11	0.00%	―	0.00%	74.27%
PCSA	29 Underperform	10.41M	-0.09	0.00%	―	0.00%	57.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Virpax Pharmaceuticals Corporate Events

Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes

On April 2, 2025, Virpax Pharmaceuticals received a delisting notice from the Nasdaq Hearings Panel due to non-compliance with the minimum stockholders’ equity requirement. The company’s stock trading will be suspended on April 4, 2025, with delisting finalized after the appeal period. Additionally, on the same day, several board members and the CFO resigned, with no disagreements cited as the cause.

Virpax Pharmaceuticals Appoints Charn Deol as Independent Director

On February 5, 2025, Virpax Pharmaceuticals appointed Charn Deol as an independent director following the resignation of Jaydriane Panis. Mr. Deol, with over 35 years of public company management experience, will also serve as Chair of the Audit Committee and join the Compensation and Nominating and Corporate Governance Committees. His appointment is expected to enhance Virpax’s strategic oversight, leveraging his extensive experience in guiding Canadian companies through public market regulatory processes.